Pieris Pharmaceuticals Inc (PIRS) Stock
PIRS is no longer traded. Pieris Pharmaceuticals was delisted from the Nasdaq in December 2024.
Prices on this page are historical; the last trade was December 13, 2024 at $12.03.
Pieris Pharmaceuticals stock price history
PIRS final trading statistics
- Final close
- $12.03
- Final trading day
- Dec 13, 2024
- Market cap at delisting
- $15.88M
- Shares outstanding
- 1.32M
- Final 52-week range
- $0.14 – $18.68
- Avg. volume (final 3 mo.)
- 17,275
- All-time high (split-adj.)
- $756.00 · Feb 2018
- All-time low (split-adj.)
- $6.53 · Jul 2024
- Return since IPO
- -94.2%
- Beta
- 0.66
- Book value / share
- $21.64
- Price / book
- 0.56
Pieris Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $42.81M | -$24.5M | -$3.79 |
| FY2022 | $25.90M | -$31.3M | -$0.45 |
| FY2021 | $31.42M | -$43.4M | -$0.69 |
| FY2020 | $29.32M | -$37.2M | -$0.68 |
| FY2019 | $46.28M | -$23.8M | -$0.55 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Pieris Pharmaceuticals stock FAQ
What happened to Pieris Pharmaceuticals stock?
Pieris Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $12.03 on December 13, 2024.
Is PIRS stock still trading?
No. PIRS was delisted from the Nasdaq in December 2024 and no longer trades on a U.S. exchange.
What was the last price of PIRS stock?
PIRS closed at $12.03 on its final trading day, December 13, 2024, for a market value of about $15.88M.
What were Pieris Pharmaceuticals's revenue and earnings in its last full fiscal year?
Pieris Pharmaceuticals reported revenue of $42.81M and net income of -$24.5M in fiscal 2023, its last full year as a public company.
When did Pieris Pharmaceuticals go public?
Pieris Pharmaceuticals Inc stock began trading on April 13, 2015.